Stephen J. Rozzo

2.7k total citations
64 papers, 2.1k citations indexed

About

Stephen J. Rozzo is a scholar working on Immunology, Rheumatology and Dermatology. According to data from OpenAlex, Stephen J. Rozzo has authored 64 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Immunology, 26 papers in Rheumatology and 12 papers in Dermatology. Recurrent topics in Stephen J. Rozzo's work include Psoriasis: Treatment and Pathogenesis (33 papers), T-cell and B-cell Immunology (24 papers) and Systemic Lupus Erythematosus Research (18 papers). Stephen J. Rozzo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (33 papers), T-cell and B-cell Immunology (24 papers) and Systemic Lupus Erythematosus Research (18 papers). Stephen J. Rozzo collaborates with scholars based in United States, Canada and United Kingdom. Stephen J. Rozzo's co-authors include Brian L. Kotzin, Timothy J. Vyse, Shozo Izui, Charles G. Drake, Gary Peltz, Divaker Choubey, John Allard, Sara A. Johnson, John C. Cambier and Ed Palmer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Immunity.

In The Last Decade

Stephen J. Rozzo

57 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen J. Rozzo United States	25	1.8k	791	359	291	280	64	2.1k
H. Richards United States	15	864 0.5×	623 0.8×	184 0.5×	160 0.5×	88 0.3×	44	1.1k
B Berner Germany	12	742 0.4×	285 0.4×	204 0.6×	71 0.2×	140 0.5×	15	1.0k
Kristina P. Callis United States	6	1.2k 0.7×	308 0.4×	517 1.4×	188 0.6×	128 0.5×	8	1.4k
A.B. Gottlieb United States	9	1.1k 0.6×	385 0.5×	539 1.5×	110 0.4×	98 0.3×	35	1.4k
Rhonda Brandon United States	6	811 0.5×	231 0.3×	270 0.8×	299 1.0×	111 0.4×	6	1.2k
Felice Rivellese United Kingdom	21	713 0.4×	452 0.6×	94 0.3×	245 0.8×	154 0.6×	54	1.4k
Yoshikata Misaki Japan	19	809 0.5×	208 0.3×	62 0.2×	221 0.8×	247 0.9×	38	1.3k
Elizabeth Whalen United States	16	725 0.4×	276 0.3×	56 0.2×	314 1.1×	157 0.6×	27	1.4k
Georg Weinlich Austria	16	582 0.3×	101 0.1×	186 0.5×	371 1.3×	389 1.4×	27	1.4k
Ann‐Christine Syvänen Sweden	15	882 0.5×	759 1.0×	16 0.0×	404 1.4×	329 1.2×	22	1.6k

Countries citing papers authored by Stephen J. Rozzo

Since Specialization

Citations

This map shows the geographic impact of Stephen J. Rozzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Rozzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Rozzo more than expected).

Fields of papers citing papers by Stephen J. Rozzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Rozzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Rozzo. The network helps show where Stephen J. Rozzo may publish in the future.

Co-authorship network of co-authors of Stephen J. Rozzo

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen J. Rozzo. A scholar is included among the top collaborators of Stephen J. Rozzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen J. Rozzo. Stephen J. Rozzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhatia, Neal, et al.. (2023). 42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB85–AB85.

Bhatia, Neal, et al.. (2023). CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis. Value in Health. 26(6). S57–S57.

Bhatia, Neal, et al.. (2023). 42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB216–AB216.

Rozzo, Stephen J., et al.. (2023). 42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB204–AB204.

Fernandez, Anthony P., E. Daudén, Sascha Gerdes, et al.. (2022). Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2. Journal of the European Academy of Dermatology and Venereology. 36(10). 1774–1783. 15 indexed citations

Imafuku, Shinichi, Hidemi Nakagawa, Atsuyuki Igarashi, et al.. (2021). Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1). The Journal of Dermatology. 48(6). 844–852. 6 indexed citations

Reich, Kristian, Richard B. Warren, Lars Iversen, et al.. (2019). Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. British Journal of Dermatology. 182(3). 605–617. 107 indexed citations

Mrowietz, Ulrich, Knud Kragballe, Kristian Reich, et al.. (2012). An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. British Journal of Dermatology. 168(2). 374–380. 15 indexed citations

Leonardi, Craig L., Kim Papp, Bruce Strober, et al.. (2011). The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. American Journal of Clinical Dermatology. 12(5). 321–337. 58 indexed citations

10.

Jørgensen, Trine N., Chao Jiang, William Loo, et al.. (2009). Development of Murine Lupus Involves the Combined Genetic Contribution of the SLAM and FcγR Intervals within the Nba2 Autoimmune Susceptibility Locus. The Journal of Immunology. 184(2). 775–786. 53 indexed citations

11.

Murakami, Masaaki, Chika Kitabayashi, Naoko Ueda, et al.. (2007). Homeostatically proliferating CD4+ T cells are involved in the pathogenesis of an Omenn syndrome murine model. Journal of Clinical Investigation. 117(5). 1270–1281. 58 indexed citations

12.

Kikuchi, Shuichi, Liliane Fossati‐Jimack, Thomas Moll, et al.. (2005). Differential Role of Three Major New Zealand Black-Derived Loci Linked with Yaa -Induced Murine Lupus Nephritis. The Journal of Immunology. 174(2). 1111–1117. 40 indexed citations

13.

Bupp, Melanie Gubbels, et al.. (2005). Effects of MHC and Gender on Lupus-Like Autoimmunity in Nba2 Congenic Mice. The Journal of Immunology. 175(9). 6190–6196. 23 indexed citations

14.

Amano, Hirofumi, Eri Amano, Marie‐Laure Santiago‐Raber, et al.. (2005). Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus. Arthritis & Rheumatism. 52(9). 2790–2798. 37 indexed citations

15.

Johnson, Sara A., Stephen J. Rozzo, & John C. Cambier. (2002). Aging-Dependent Exclusion of Antigen-Inexperienced Cells from the Peripheral B Cell Repertoire. The Journal of Immunology. 168(10). 5014–5023. 110 indexed citations

16.

Tucker, Rebecca M., Timothy J. Vyse, Stephen J. Rozzo, et al.. (2000). Genetic Control of Glycoprotein 70 Autoantigen Production and Its Influence on Immune Complex Levels and Nephritis in Murine Lupus. The Journal of Immunology. 165(3). 1665–1672. 33 indexed citations

17.

Vyse, Timothy J., Charles G. Drake, Stephen J. Rozzo, et al.. (1996). Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice.. Journal of Clinical Investigation. 98(8). 1762–1772. 90 indexed citations

18.

Drake, Charles G., Stephen J. Rozzo, Timothy J. Vyse, & Brian L. Kotzin. (1996). Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice. Mammalian Genome. 7(6). 466–467. 3 indexed citations

19.

Rozzo, Stephen J., et al.. (1995). Analysis of the New Zealand Black contribution to lupus-like renal disease. The Journal of Immunology. 154(5). 21 indexed citations

20.

Rozzo, Stephen J., et al.. (1985). Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens.. The Journal of Immunology. 134(3). 1723–1727. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact